ABSTRACT

Introduction  Type 1 diabetes is heterogeneous in its presentation and progression. Variations in clinical presentation between children and adults, and with ethnic group warrant further study in the UK to improve understanding of this heterogeneity. Early interventions to limit beta cell damage in type 1 diabetes are undergoing evaluation, but recruitment is challenging. The protocol presented describes recruitment of people with clinician-assigned, new-onset type 1 diabetes to understand the variation in their manner of clinical presentation, to facilitate recruitment into intervention studies and to create an open-access resource of data and biological samples for future type 1 diabetes research.

Methods and analysis  Using the National Institute for Health Research Clinical Research Network, patients >5 years of age diagnosed clinically with type 1 diabetes (and their siblings) are recruited within 6 months of diagnosis. Participants agree to have their clinical, laboratory and demographic data stored on a secure database, for their clinical progress to be monitored using information held by NHS Digital, and to be contacted about additional research, including immunotherapy and other interventions. An optional blood sample is taken for islet autoantibody measurement and storage of blood and DNA for future analyses. Data will be analysed statistically to describe the presentation of incident type 1 diabetes in a contemporary UK population.

Ethics and dissemination  Ethical approval was obtained from the independent NHS Research Ethics Service. Results will be presented at national and international meetings and submitted for publication to peer-reviewed journals.

INTRODUCTION

Type 1 diabetes (T1D) is the most common form of diabetes in childhood, but it is frequently diagnosed in adults. In the UK it is most common in people of white European descent, but also affects other ethnic groups, and it is heterogeneous in initial clinical presentation and in its progression. Markers of autoimmunity, such as antibodies to islet antigens, most commonly glutamate decarboxylase (GADA), insulin itself, islet antigen 2 (IA-2A) and zinc transporter-T8 (ZnT-8A), are frequently, but not always detectable at onset in people with a clinical diagnosis of T1D. Measurement of autoantibodies is advocated by many to aid diabetes classification, but only recommended in the UK when knowledge of autoantibody status (positive/negative) would have implications for clinical management or access to treatment (eg, ‘insulin pump’ therapy). Few T1D cohorts include both children and adults and, where studied, clinical characteristics and autoantibody frequencies have been found to vary between children and adults at onset. Additionally, descriptions of adult-onset diabetes with autoantibodies have highlighted differences in T1D phenotype at onset between adults and children. Reports of the variation of autoantibody status...
and frequency with ethnicity are also scarce and have revealed a somewhat conflicting picture.\(^6\)\(^1\)\(^8\)–\(^20\) Differences in presenting features of T1D with autoantibody status warrant further investigation in children and adults in the multiethnic UK population to improve understanding of the heterogeneity of T1D. People with T1D have a lifelong dependency on treatment with exogenous insulin, resulting from an autoimmune destruction of pancreatic beta cells. Early intervention therapies are emerging that aim to limit this autoimmune destruction and preserve beta cell function.\(^21\)\(^22\) Preservation of even modest levels of insulin secretion has been shown to reduce the risk of developing diabetic complications, improve glycaemic control and may also protect against severe hypoglycaemia.\(^23\)\(^\)\(^24\) Many investigational therapies target new-onset T1D — at a stage when there is still significant insulin secretion to preserve. Recruitment to trials in new-onset T1D is challenging, in part because individual centres see a relatively small number of incident cases per year. The aims of the After Diabetes Diagnosis REsearch Support System (ADDRESS) are therefore the following:

1. to characterise people with clinician-assigned, new-onset T1D, demographically, clinically and by islet autoantibody status, in a national, multiethnic cohort, and to perform hypothesis-generating analyses investigating the heterogeneity of clinical presentation

2. to use the cohort of children and adults with incident T1D and their siblings to support recruitment into T1D trials and other clinical research studies by providing them with information about studies for which they might be eligible (initially in new-onset T1D, and with time, studies in established T1D, or studies for first-degree relatives), thereby also increasing opportunities to participate in research among patients and their families

3. to establish an open-access resource of data and biological samples, including DNA, collected close to diagnosis for use in other T1D research, forming, in particular, a foundation for prospective studies from the time of diagnosis.

There are a number of ongoing initiatives in the USA and Europe to characterise people with incident T1D, some of which include the banking of biological samples and open access to samples or data, some that include the study of first-degree relatives, and some that also support the conduct of clinical trials. Exemplar initiatives are summarised in Table 1, in comparison with ADDRESS. There are T1D registries in the UK primarily set up to drive improvements in clinical care, and the notable open-access Warren repository,\(^25\) established to further understanding of T1D genetic susceptibility. There are, however, no national, multiethnic collections of data and biological samples from both children and adults with incident T1D in the UK. The Scottish Health Research register SHARE is an example of another national resource that supports recruitment to clinical research, although unlike ADDRESS it does not focus on new-onset T1D.\(^26\) The features of these UK-specific T1D registries and resources are summarised in Table 2.

In 2006 the National Institute for Health Research Clinical Research Network (NIHR CRN) was set up as the research delivery arm of the National Health Service (NHS) in England. The universal health coverage of the NHS, coupled with the NIHR CRN, makes the UK a particularly suitable environment for studies in new-onset T1D. This is further strengthened via linkage with the ADDRESS new-onset T1D ascertainment network, which is dedicated to identifying people with incident T1D shortly after diagnosis and offering them and their siblings entry into T1D clinical research studies. ADDRESS is a partner in the TIDUK Consortium, formed in 2015 to promote, support and develop immunotherapy research in the UK via a network of centres to conduct clinical trials, and a mechanistic core to conduct state-of-the-art assays to study the immunology of T1D and the mechanisms of action of immunotherapies.

**METHODS AND ANALYSIS**

**Establishment of the cohort**

The After Diabetes Diagnosis REsearch Support System (previously referred to as ADDRESS or ADDRESS-2, hereafter as ADDRESS) started in pilot form in 2008 to establish the ‘proof of concept’ that ascertainment and recruitment of people with incident T1D shortly after diagnosis were feasible in substantial numbers using the resources of the NIHR CRN. Patients with a clinician-assigned diagnosis of T1D were recruited if they agreed to have their data on a database and to be contacted about other research projects for which they might be eligible. Clinical and demographic information, including the participant’s unique NHS identifier, was obtained for analysis, but no biological samples were collected. This pilot was established in 78 recruiting hospitals in England and Wales. NIHR CRN staff recruited 645 participants between 2008 and 2010. With cofunding from Diabetes UK and the Juvenile Diabetes Research Foundation, and with separate NHS Research Ethics Committee review, the project was expanded to its present and ongoing form in January 2011 in which 156 hospitals are participating in 124 NHS Trusts across England and Health Boards in Wales. Figure 1 illustrates the timeline of development of ADDRESS, and figure 2 shows the locations of centres participating currently. The NIHR CRN structure provides research support via 15 local branches in England and a related system exists to support diabetes research in Wales.

**Inclusion and exclusion criteria**

During the first 3 years of the current study (2011–2014), people with a clinician-assigned diagnosis of T1D aged 5–60 years were recruited within 6 months of diagnosis. From October 2014 the upper age limit was removed to allow newly diagnosed adults over the age of 60 to participate. People initially diagnosed with another diabetes...
Table 1  Exemplar initiatives to characterise incident T1D, in comparison with ADDRESS

<table>
<thead>
<tr>
<th>Title</th>
<th>Country</th>
<th>Geographical coverage</th>
<th>Diabetes subtypes</th>
<th>Relatives of proband</th>
<th>Recruitment age (years)</th>
<th>Multiethnic</th>
<th>Biological sample collection</th>
<th>Accessible data or biological samples</th>
<th>Consent to be approached about other research</th>
<th>Year initiated</th>
<th>Aims</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEARCH for Diabetes in Youth Study</td>
<td>USA</td>
<td>Five regional centres</td>
<td>All</td>
<td>No</td>
<td>&lt;20</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
<td>Unknown</td>
<td>2000</td>
<td>To determine temporal changes in incidence and prevalence of diabetes in young people by subtype, age, gender and ethnicity, and to aid classification of subtype</td>
</tr>
<tr>
<td>T1D Exchange registry</td>
<td>USA</td>
<td>77 centres in 35 states</td>
<td>T1D</td>
<td>No</td>
<td>Children and adults of any age</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (75% of cohort)</td>
<td>2010</td>
<td>To identify issues of clinical relevance, generate hypotheses and characterise patients for future studies</td>
</tr>
<tr>
<td>Belgian Diabetes Registry</td>
<td>Belgium</td>
<td>Belgium-wide with national network of centres to conduct clinical trials</td>
<td>T1D</td>
<td>First-degree relatives</td>
<td>&lt;40</td>
<td>Unknown</td>
<td>Yes</td>
<td>Unknown</td>
<td>Yes</td>
<td>1989</td>
<td>To detect trends in incidence over time, to identify markers of T1D onset and progression, and to conduct trials</td>
</tr>
<tr>
<td>BOX</td>
<td>UK</td>
<td>Six centres in the former Oxford Regional Health Authority area</td>
<td>T1D</td>
<td>First-degree relatives</td>
<td>≤21</td>
<td>Unknown</td>
<td>(there is little ethnic diversity in the region)</td>
<td>Yes</td>
<td>No</td>
<td>1985</td>
<td>To study the natural history of T1D, including initiation and progression of islet autoimmunity to identify those at risk of developing T1D, and to determine temporal changes in incidence</td>
</tr>
<tr>
<td>ADDRESS</td>
<td>UK</td>
<td>156 centres across England and Wales</td>
<td>T1D</td>
<td>Siblings</td>
<td>≥5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2007</td>
<td>To study the heterogeneity of clinical presentation, to support recruitment into clinical trials and other studies, and to facilitate genetic and biomarker research</td>
</tr>
<tr>
<td>Title</td>
<td>Type of collection</td>
<td>Diabetes subtypes</td>
<td>Relatives of proband</td>
<td>Recruitment age (years)</td>
<td>Incident/prevalent</td>
<td>Multiethnic</td>
<td>Biological sample collection</td>
<td>Accessible data or biological samples</td>
<td>Consent to be approached about other research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>------------</td>
<td>----------------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 1 diabetes Warren repository[25]</td>
<td>DNA and cell lines (collected during 1990–1995)</td>
<td>T1D</td>
<td>Multiplex families (two affected children); at least one diagnosed under 17 years of age and other(s) diagnosed under 29 years, with two living parents</td>
<td>Children and adults</td>
<td>Prevalent</td>
<td>No: white European only</td>
<td>Yes (DNA)</td>
<td>Yes</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Children and Young People’s Diabetes Network, <a href="http://www.cypdiabetesnetwork.nhs.uk">www.cypdiabetesnetwork.nhs.uk</a></td>
<td>National register in Wales and regional registries in England[36]</td>
<td>All</td>
<td>No</td>
<td>&lt;19</td>
<td>Incident and prevalent</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Scottish Care Information – Diabetes Collaboration, <a href="http://www.sci-diabetes.scot.nhs.uk">www.sci-diabetes.scot.nhs.uk</a></td>
<td>Register and shared electronic patient record</td>
<td>All</td>
<td>No</td>
<td>Children and adults</td>
<td>Incident and prevalent</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Scottish Health Research register SHARE[26]</td>
<td>Register of people living in Scotland who have declared their interest in taking part in health research</td>
<td>All (supports recruitment to research across all clinical specialties, not diabetes-specific)</td>
<td>Unknown</td>
<td>&gt;16</td>
<td>Unknown</td>
<td>Yes</td>
<td>Storage of remainder of routine clinical samples</td>
<td>Unknown</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
subtype and later reassigned a diagnosis of T1D are eligible if still within 6 months of the initial diagnosis. Adults who are not competent to give consent are excluded. People who took part in the pilot form of ADDRESS are eligible to be recruited to the current study, and their individual data are transferred from the pilot into the current study.

Sample size

The annual incidence of T1D in the UK is 22–30 per 100,000 in the 0–14 years age group, with an estimated 76% of incident cases aged 5–14 years. There is a paucity of incidence data for adults worldwide, but one UK study reported an incidence of 12 per 100,000 for those aged 15–34 years. Therefore, we estimate that 3900–4500 children and adults will be diagnosed per year in the current recruitment age range in England and Wales.

Recruitment

Methods vary depending on local resources and preferences, but local researchers (NIHR CRN research nurses and/or other local research nurses and physicians) perform the recruitment mainly via secondary care and specialist diabetes centres, as patients (both children and adults) are mostly seen clinically in these settings. Recruiting staff in the NIHR CRN have been trained to approach patients and families with sensitivity soon after diagnosis and to take informed consent. Permission is sought from the patient or parent/guardian to approach siblings. The patients, their siblings and the parent/guardian for children aged 5–15 years are provided with age-specific information sheets about the study by the local researcher. Informed consent is sought at least 1 week after diagnosis and at least 48 hours after the information sheets have been given. Recruitment support initiatives have included providing NHS clinical care teams with information about T1D research, displaying posters about ADDRESS and providing patients with leaflets introducing clinical research and ADDRESS in clinic and in packs for newly diagnosed patients. A website provides additional information.

Consent

ADDRESS operates a two-tier consent model: for tier 1, participants provide written informed consent for their health and contact details to be held on a database and for their being contacted about studies. They also consent to follow-up using information held by NHS Digital and the Office for National Statistics (ONS). With additional second-tier consent, participants may choose to donate blood samples for islet autoantibody analysis and storage of blood and DNA for future use in diabetes research.

Data collection

At the time of recruitment participant information is collected via interview with the participant or parent/guardian, and from specialist care medical records, as shown in table 3. Ethnicity is self-reported as one of 16 categories, following UK ONS guidance on collecting ethnic group data. A diagnosis of parental or grandparental diabetes is recorded without subtype because historical classifications may be incorrect or incomplete. Laboratory test results are recorded from those tests performed locally as part of routine clinical care. A diagnosis of ketoacidosis at presentation is recorded if assigned by the local clinical team, or if all of the following were documented in the clinical records: glucose >11 mmol/L; blood ketone bodies >3 mmol/L or urine ketones levels positive ++; pH < 7.3; and/or bicarbonate < 15 mmol/L. Except for the additional specialist care information available for patients, similar data are collected at baseline for siblings.

Project-specific blood sampling

Sample donation is a voluntary component of ADDRESS, currently for participants with T1D only (prior to October 2014, siblings were also given the option of donating samples). Random blood samples are collected and sent at ambient temperature via standard post to the Public Health England European Collection of Cell Cultures at Porton Down, UK, which operates in accordance with the UK Human Tissue Act 2004. Serum (from a serum separation tube) and peripheral blood lymphocytes (PBLs, from an acid citrate dextrose tube) are separated on arrival. An EDTA tube is frozen for later DNA extraction (median: 2 (IQR: 1–3) days after sampling). The samples are stored in coded, pseudoanonymised format and include serum from coagulated blood, extracted and
resuspended DNA, PBLs, and lymphoblastoid cell lines (LCLs) derived by Epstein-Barr virus transformation of thawed PBLs. Samples are stored at –80°C and PBLs and LCLs are placed in liquid nitrogen for cryopreservation for the duration of the study. An aliquot (0.5 mL) of serum from each blood sample is sent to the University of Bristol for autoantibody measurements.

**Islet autoantibody measurement**

Autoantibodies to GADA, IA-2A and ZnT-8A are measured in participants with T1D using established radiobinding assays. Insulin autoantibodies are not measured as these people are receiving exogenous insulin therapy, which could itself induce an immune response.
Table 3  Data and associated methods of collection for participants with incident T1D and for sibling participants at the time of recruitment

<table>
<thead>
<tr>
<th>Data</th>
<th>Incident T1D</th>
<th>Via validated against medical records</th>
<th>Sibling</th>
<th>Via interview or at visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact details and unique NHS identifier</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>General practitioner (GP) details (GP is informed of the person’s participation)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes care physician details (physician is informed of the person’s participation if not the principal investigator at the research site)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic information including self-reported ethnic origin</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of diagnosis, clinical presentation and duration of symptoms (presentation with diabetic ketoacidosis, polyuria/polydipsia, weight loss, fatigue, abdominal pain,* fasting or random plasma glucose)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current diabetes treatment regimen, including date insulin first administered</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-diabetic medication</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history including history of autoimmune diseases (Addison’s disease, coeliac disease, hyperthyroidism, hypothyroidism and vitiligo) and of gestational diabetes</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family medical history including parental and grandparental history of diabetes, hypertension, myocardial infarction and stroke, along with sibling demographics and diabetes history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical measures, including blood pressure, weight and height using standard protocols</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood biochemistry including glycated haemoglobin (HbA1c) (mmol/mol), fasting or random plasma glucose (mmol/L), oral glucose tolerance test results (mmol/L) if performed locally and C-peptide levels (nmol/L) if performed locally</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details of diabetes structured education offered/scheduled/completed*</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Collected for participants recruited from February 2015 onwards.

T1D, type 1 diabetes; NHS, National Health Service.

Antigens radiolabelled with $^{35}$S methionine are expressed using a TNT in vitro reticulocyte lysate quick coupled transcription/translation system kit (Promega, Madison, Wisconsin, USA) with plasmids encoding full-length GAD65, the intracytoplasmic region of IA-2 (aa 606–979), and the 325-arginine (ZnT8R) and 325-tryptophan (ZnT8W) isoforms of the C-terminal region of ZnT8 (aa268-379). Immunocomplexes formed following incubation of sera with radiolabelled antigens are precipitated with Protein A-Sepharose (GE Healthcare Life Sciences, Little Chalfont, Bucks, UK), washed and counted in a TopCount beta counter (PerkinElmer, Waltham, Massachusetts, USA).

Results are expressed in digestive and kidney (DK) units/mL (GADA and IA-2A) or arbitrary units (ZnT8A) after reference to standard curves consisting of dilutions of patient sera in antibody-negative sera from healthy donors. Thresholds are set at the 97th percentile of 974 control samples for GADA, the 98th percentile of 500 control samples for IA-2A and the 97.5th percentile of 523 healthy schoolchildren for ZnT8A. The GADA assay achieves a sensitivity of 74% at 96.7% specificity, while the IA-2A, ZnT8RA and ZnT8WA assays achieve sensitivities of 72%, 60% and 46%, respectively, at 100% specificity, in the 2015 Islet Autoantibody Standardization Program Workshop. Interassay coefficients of variation of high and moderate/low positive samples, respectively, were 18% and 18% for GADA, 19% and 17% for IA-2A, 22% and 16% for ZnT8RA, and 25% and 20% for ZnT8WA.

Follow-up data collection and verification

Participants with T1D are reviewed via their medical records at 4–8 months following diagnosis to verify that their original clinical diabetes classification has not been changed by their clinicians. Data reviewed at the follow-up are shown in table 4.

An application to NHS Digital and the UK ONS is planned for tracing change of postal address, mortality flagging and access to hospital admission data (Hospital Episode Statistics).

Database

Data are entered into a secure electronic data capture and management system designed specifically for clinical
research. All information is stored in accordance with the UK Data Protection Act (1998).

Recruitment into other studies

Eligible participants are given information at intervals about specific diabetes trials/research studies by the central study team or local researchers. Information is retained on those previously contacted about research and whether or not they are currently participating in a study.

Data analysis plan

The collected data allow generation and testing of hypotheses about the presentation of clinician-assigned T1D and other characteristics early after diagnosis. Our aim is to compare characteristics between groups: for example, islet autoantibody positive and negative; ethnicity groupings of white European, South Asian (including Indian, Pakistani and Bangladeshi) and African-Caribbean (black African or black Caribbean); and children and adults. We aim also to investigate the relationships between insulin dose and glycaemic control. Recorded variables are categorised as ‘Individual Characteristics’ (eg, age, gender, child/adult, birth weight, ethnicity, history of other autoimmune disease, parent with diabetes, sibling with diabetes), ‘Diabetes Presentation’ (eg, ketoacidosis at T1D presentation, osmotic symptoms (polydipsia/polyuria), weight loss, fatigue, symptom duration, initial insulin dose and autoantibody status) and ‘Diabetes Characteristics’ (eg, insulin dose, glycated haemoglobin (HbA1c) at time points after presentation).

Table 4 Data collection for participants with incident T1D at 4–8 months postdiagnosis and at least 2 months after the time of recruitment

<table>
<thead>
<tr>
<th>Data</th>
<th>Incident T1D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmation of, or change in classification of, diabetes subtype</td>
<td>X</td>
</tr>
<tr>
<td>Occurrence of diabetic ketoacidosis since diagnosis*</td>
<td>X</td>
</tr>
<tr>
<td>Any change in diabetes treatment or dose, and concurrent medication</td>
<td>X</td>
</tr>
<tr>
<td>Clinical measures, including blood pressure, weight and height</td>
<td>X</td>
</tr>
<tr>
<td>Blood biochemistry including glycated haemoglobin (HbA1c) (mmol/mol), fasting or random plasma glucose (mmol/L), oral glucose tolerance test results (mmol/L) if performed locally and C-peptide levels (nmol/L) if performed locally</td>
<td>X</td>
</tr>
<tr>
<td>Details of diabetes structured education offered/scheduled/completed*</td>
<td>X</td>
</tr>
</tbody>
</table>

*All data are collected from medical records.

*Collected for participants recruited from February 2015 onwards.

T1D, type 1 diabetes.

ETHICS AND DISSEMINATION

Ethical approval was obtained from the NHS Research Ethics Committee - South Central-Berkshire (reference 10/H0505/85), and each participating NHS Trust submitted a Site-Specific Assessment in order to participate. The project is conducted in accordance with the recommendations for physicians involved in research on human subjects by the 18th World Medical Assembly, Helsinki 1964 and later revisions. The International Conference on Harmonisation Guideline for Good Clinical Practice (Topic E6 — 10 June 1996) and participant confidentiality are maintained throughout.

ADDRESS is an accessible resource for clinical and academic researchers, both as an infrastructure to identify and contact candidates for recruitment into T1D studies and as an open-access database and biological sample repository. Access is through a management committee comprised of lay people, scientists and clinical investigators representing relevant T1D research interests. Researchers wishing to use the ADDRESS-2 resource can apply to the ADDRESS-2 Management Committee. The access process and associated documents are described on the study website (www.address2.org).

Ethical approval will be sought for continuing use of the data every 5 years (current approval is to the end of 2019). Every effort will be made to sustain this open-access resource beyond the present funding term. The database will be maintained by Imperial College London. The biological samples will continue to be stored for as long as there is funding to support the repository.

The results arising from this project will be presented at national and international meetings, and submitted for publication to peer-reviewed medical journals.

Acknowledgements The authors would like to thank Professor Nish Chaturvedi, now at University College London, and Dr Bob Goldstein at the Juvenile Diabetes Research Foundation for their input and advice.

Contributors The vision for an ascertainment network was that of DJG in consultation with funders. Recruitment, data collection and analysis were designed and refined by DJG, HCW, NO, VB, AK, SM and DBD. Islet autoantibody analysis was designed by PJB and AKJW. The statistical analysis plan was written by IFG. Procedures for open access were drafted by HCW and ratified by the ADDRESS-2 Management Committee.

Funding This work was supported by Diabetes UK grant number 09/0003919 and the Juvenile Diabetes Research Foundation grant number 9-2010-407. Recruitment is supported by staff at the National Institute for Health Research Clinical Research Network.

Competing interests None declared.

Ethics approval NHS Research Ethics Committee (South Central-Berkshire).
REFERENCES


Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study

Helen C Walkey, Akaal Kaur, Vassiliki Bravis, Ian F Godsland, Shivani Misra, Alistair J K Williams, Polly J Bingley, David B Dunger, Nick Oliver and Desmond G Johnston

BMJ Open 2017 7:
doi: 10.1136/bmjopen-2016-013956

Updated information and services can be found at:
http://bmjopen.bmj.com/content/7/7/e013956

References

These include:

This article cites 34 articles, 13 of which you can access for free at:
http://bmjopen.bmj.com/content/7/7/e013956#BIBL

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Diabetes and Endocrinology (421)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/